Clinical neuropharmacology · 2012
Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bosco Domenico, Plastino Massimiliano, Colica Carmela, Bosco Francesca, Arianna Spanò, Vecchio Antonino, Galati Francesco, Cristiano Dario, Consoli Arturo, Consoli Domenico
Аннотация
UNLABELLED: Pathological gambling (PG) is a potential complication related to the treatment of Parkinson disease (PD) with dopamine agonists (DA). The cause of this disorder is unknown, but altered dopamine neurotransmission may be involved.
OBJECTIVE: We evaluated the efficacy and tolerability of the opioid antagonist naltrexone in the treatment of PG in PD.
METHODS: Our cases included 3 patients with PD who developed PG after DA treatment.
RESULTS: Pathological gambling did not improve after reduction or discontinuation of DA. These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG. Naltrexone treatment was well tolerated. In one patient, higher dose of naltrexone resulted in hepatic abnormalities, which resolved after dosage reduction.
CONCLUSIONS: The opioid antagonist naltrexone could be an effective option for the treatment of PG in PD.
OBJECTIVE: We evaluated the efficacy and tolerability of the opioid antagonist naltrexone in the treatment of PG in PD.
METHODS: Our cases included 3 patients with PD who developed PG after DA treatment.
RESULTS: Pathological gambling did not improve after reduction or discontinuation of DA. These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG. Naltrexone treatment was well tolerated. In one patient, higher dose of naltrexone resulted in hepatic abnormalities, which resolved after dosage reduction.
CONCLUSIONS: The opioid antagonist naltrexone could be an effective option for the treatment of PG in PD.